# A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

> **NCT07428616** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Exelixis** · enrollment: 100 (estimated)

## Conditions studied

- Meningioma

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07428616
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-02
- **Final completion:** 2029-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07428616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07428616, "A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07428616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*